Glycopyrrolate — $0 on Listed Strengths
Glycopyrrolate is $0 on listed strengths only. Other strengths are not a blanket $0.
Glycopyrrolate Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $39.00 |
$0 on listed strengths: 1mg Tablets (max 180); 2mg Tablets (max 180)
About Glycopyrrolate
Glycopyrrolate is a prescription medication. Ask your doctor if Glycopyrrolate is right for you.
How to Check Glycopyrrolate Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Glycopyrrolate at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Glycopyrrolate is approved for (FDA label)
Glycopyrrolate Oral Solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). Glycopyrrolate Oral Solution is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). (1)
Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Glycopyrrolate (FDA label)
Glycopyrrolate Oral Solution is available as a clear, cherry-flavored solution for oral administration in 16 ounce bottles. 1 mg/5 mL, oral solution in 16 ounce bottles. (3)
Source: FDA prescribing information (DailyMed). Set ID: 62e1ba35-bc84-4818-be54-8b534a1bf93c. SPL document ID: 81a768f1-afb8-45a3-abe9-09451a80db07. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Glycopyrrolate (FDA label)
The following serious adverse reactions are described elsewhere in the labeling: Constipation or intestinal pseudo-obstruction [see Warnings and Precautions (5.1) ] Incomplete mechanical intestinal obstruction [see Warnings and Precautions (5.2) ] The most common adverse reactions reported with Glycopyrrolate Oral Solution are dry mouth, vomiting, constipation, flushing, and nasal congestion. The most common adverse reactions (incidence ≥30%) are dry mouth, vomiting, constipation, flushing, and nasal congestion.
Source: FDA prescribing information (DailyMed). Set ID: 62e1ba35-bc84-4818-be54-8b534a1bf93c. SPL document ID: 81a768f1-afb8-45a3-abe9-09451a80db07. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Glycopyrrolate (FDA label)
Glycopyrrolate Oral Solution is contraindicated in: Patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis). Patients taking solid oral dosage forms of potassium chloride. The passage of potassium chloride tablets through the gastrointestinal (GI) tract may be arrested or delayed with coadministration of Glycopyrrolate Oral Solution. Medical conditions that preclude anticholinergic therapy. (4) Concomitant use of solid oral dosage forms of potassium chloride. (4)
Source: FDA prescribing information (DailyMed). Set ID: 62e1ba35-bc84-4818-be54-8b534a1bf93c. SPL document ID: 81a768f1-afb8-45a3-abe9-09451a80db07. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Glycopyrrolate (FDA label)
Constipation or intestinal pseudo-obstruction: May present as abdominal distention, pain, nausea, or vomiting. Assess patients for constipation, particularly within 4-5 days of initial dosing or after a dose increase. (5.1) Incomplete mechanical intestinal obstruction: May present as diarrhea. If obstruction is suspected, discontinue Glycopyrrolate Oral Solution and evaluate. (5.2) High ambient temperature: To reduce the risk of heat prostration, avoid high temperatures. (5.3) 5.1 Constipation or Intestinal Pseudo-obstruction Constipation is a common dose-limiting adverse reaction which sometimes leads to glycopyrrolate discontinuation [see Adverse Reactions (6.1) ]. Assess patients for constipation, particularly within 4-5 days of initial dosing or after a dose increase. Intestinal pseudo-obstruction has been reported and may present as abdominal distention, pain, nausea or vomiting. 5.2 Incomplete Mechanical Intestinal Obstruction Diarrhea may be an early symptom of incomplete mechanical intestinal obstruction, especially in patients with ileostomy or colostomy.
Source: FDA prescribing information (DailyMed). Set ID: 62e1ba35-bc84-4818-be54-8b534a1bf93c. SPL document ID: 81a768f1-afb8-45a3-abe9-09451a80db07. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Glycopyrrolate (FDA label)
Drugs Affected by Reduced GI Transit Time Glycopyrrolate reduces GI transit time, which may result in altered release of certain drugs when formulated in delayed-or controlled-release dosage forms. The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4) ]. Digoxin administered as slow dissolution oral tablets may have increased serum levels and enhanced action when administered with glycopyrrolate. Monitor patients receiving slow dissolution digoxin for increased action if glycopyrrolate is coadministered regularly. Consider the use of other oral dosage forms of digoxin (e.g., elixir or capsules). Amantadine The anticholinergic effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during coadministration of amantadine. Drugs Whose Plasma Levels May be Increased by Glycopyrrolate Coadministration of glycopyrrolate may result in increased levels of certain drugs.
Source: FDA prescribing information (DailyMed). Set ID: 62e1ba35-bc84-4818-be54-8b534a1bf93c. SPL document ID: 81a768f1-afb8-45a3-abe9-09451a80db07. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.